Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $25.67.

A number of equities analysts have recently commented on ATXS shares. Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, February 27th. Finally, JMP Securities assumed coverage on shares of Astria Therapeutics in a research report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target on the stock.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ATXS. Charles Schwab Investment Management Inc. boosted its stake in Astria Therapeutics by 152.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after buying an additional 189,727 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Astria Therapeutics during the third quarter worth $613,000. FMR LLC boosted its stake in Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares in the last quarter. Barclays PLC boosted its stake in Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 38,321 shares in the last quarter. Finally, Vestal Point Capital LP boosted its stake in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Stock Down 5.3 %

NASDAQ:ATXS opened at $6.10 on Tuesday. Astria Therapeutics has a 12 month low of $6.07 and a 12 month high of $16.90. The firm has a market cap of $344.25 million, a price-to-earnings ratio of -2.92 and a beta of 0.67. The company’s 50 day moving average is $7.63 and its 200-day moving average is $9.85.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.